1] Division of Neuroscience Research, Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, USA [2] Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN, USA [3] Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN, USA.
Transl Psychiatry. 2013 Sep 10;3(9):e303. doi: 10.1038/tp.2013.64.
There is abundant evidence that dysfunction of the γ-aminobutyric acid (GABA)ergic signaling system is implicated in the pathology of schizophrenia and mood disorders. Less is known about the alterations in protein expression of GABA receptor subunits in brains of subjects with schizophrenia and mood disorders. We have previously demonstrated reduced expression of GABA(B) receptor subunits 1 and 2 (GABBR1 and GABBR2) in the lateral cerebella of subjects with schizophrenia, bipolar disorder and major depressive disorder. In the current study, we have expanded these studies to examine the mRNA and protein expression of 12 GABA(A) subunit proteins (α1, α2, α3, α5, α6, β1, β2, β3, δ, ε, γ2 and γ3) in the lateral cerebella from the same set of subjects with schizophrenia (N=9-15), bipolar disorder (N=10-15) and major depression (N=12-15) versus healthy controls (N=10-15). We found significant group effects for protein levels of the α2-, β1- and ε-subunits across treatment groups. We also found a significant group effect for mRNA levels of the α1-subunit across treatment groups. New avenues for treatment, such as the use of neurosteroids to promote GABA modulation, could potentially ameliorate GABAergic dysfunction in these disorders.
有大量证据表明,γ-氨基丁酸(GABA)能信号系统的功能障碍与精神分裂症和情绪障碍的病理学有关。关于精神分裂症和情绪障碍患者大脑中 GABA 受体亚基蛋白表达的改变知之甚少。我们之前已经证明,在精神分裂症、双相情感障碍和重度抑郁症患者的外侧小脑中,GABA(B)受体亚基 1 和 2(GABBR1 和 GABBR2)的表达减少。在当前的研究中,我们扩展了这些研究,以检查来自同一组精神分裂症(N=9-15)、双相情感障碍(N=10-15)和重度抑郁症(N=12-15)患者与健康对照组(N=10-15)的外侧小脑中 12 种 GABA(A)亚基蛋白(α1、α2、α3、α5、α6、β1、β2、β3、δ、ε、γ2 和 γ3)的 mRNA 和蛋白表达。我们发现,治疗组的 α2、β1 和 ε 亚基的蛋白水平存在显著的组间效应。我们还发现,治疗组的 α1 亚基的 mRNA 水平存在显著的组间效应。新的治疗途径,如使用神经甾体促进 GABA 调节,可能潜在地改善这些疾病中的 GABA 能功能障碍。